2014
DOI: 10.1016/j.pnpbp.2014.02.003
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Excessive weight gain has been identified as a serious metabolic side-effect of second-generation antipsychotics (SGAs), including olanzapine. While hyperphagia has been suggested to be the main contributor for this side-effect in the short term, reduced energy expenditure, in particular thermogenesis and locomotor activity, has been considered to contribute to the maintenance of heavy weight under long-term SGA treatments. Recent studies have identified metabolically active brown adipose tissues (BAT) in adul… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

9
36
0
1

Year Published

2014
2014
2021
2021

Publication Types

Select...
8
1

Relationship

3
6

Authors

Journals

citations
Cited by 52 publications
(46 citation statements)
references
References 29 publications
9
36
0
1
Order By: Relevance
“…We used a hyperlipidemia mouse model to investigate the mechanism. We found that olanzapine could deregulate the adiposity of BAT as evidenced by the increased whiting of BAT, which agreed with previous findings that olanzapine upregulated aP2 expression, the marker of WAT adipocytes, but downregulated UCP1 expression, the marker of BAT adipocytes, in adipose tissues of rats [33,34]. To date, the detailed mechanism underlying the whiting of BAT is not fully understood.…”
Section: Discussionsupporting
confidence: 90%
“…We used a hyperlipidemia mouse model to investigate the mechanism. We found that olanzapine could deregulate the adiposity of BAT as evidenced by the increased whiting of BAT, which agreed with previous findings that olanzapine upregulated aP2 expression, the marker of WAT adipocytes, but downregulated UCP1 expression, the marker of BAT adipocytes, in adipose tissues of rats [33,34]. To date, the detailed mechanism underlying the whiting of BAT is not fully understood.…”
Section: Discussionsupporting
confidence: 90%
“…It is worth noting that weight gain induced by antipsychotics is not only attributed to increased energy intake; reduced energy expenditure may also play an important role as proven in olanzapine-induced weight gain rat models [38,39,56,72]. In fact, this study found that risperidone reduced locomotor activity in juvenile female rats, which is consistent with a number of studies in which risperidone was proven to reduce locomotor activity in rats and mice [53,73,74].…”
Section: Reduced Locomotor Activitysupporting
confidence: 90%
“…Therefore, in this study, we investigated the effects of risperidone on body weight and food intake in female juvenile rats and further investigated its effects on expression of hypothalamic H 1 R, NPY, POMC, AgRP and CART mRNA expression, and their relationships with changes in body weight gain and food intake. Since our recent studies in adult rat models have demonstrated that olanzapine-induced weight gain is associated with a significant decrease in locomotor activity [38][39][40], and decreased activity was also observed after acute administration of antipsychotics during early development [41], the locomotor activity of female juvenile rats was also examined in this study.…”
Section: Introductionmentioning
confidence: 99%
“…Chronic co-treatment with betahistine also reversed the attenuated BAT UCP 1 and PGC-1α expressions, which illustrated that the two biomarkers of thermogenesis were involved in the decreased energy expenditure and increased weight gain induced by chronic olanzapine treatment [65]. Furthermore, the negative correlation between hypothalamic pAMPKα, and BAT UCP 1 and PGC-1α levels, is in line with the previous report about hypothalamic AMPK modulating BAT thermogenesis, and UCP 1 and PGC-1α expression [184][185][186][187].…”
Section: The Mechanisms Underlying Betahistine In Reducing Antipsychosupporting
confidence: 89%